Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has issued an update.
Mayne Pharma Group Limited has notified the market of the issue of 25,592 new ordinary fully paid shares following the conversion or exercise of previously unquoted equity securities, effective 31 December 2025. The modest increase in issued capital reflects the crystallisation of existing equity incentives or convertible instruments, marginally diluting existing shareholders while signalling ongoing utilisation of equity-based funding and remuneration typical for companies in the pharmaceutical sector.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company listed on the ASX under the code MYX. The company develops and manufactures branded and generic medicines, with a focus on complex and hard-to-formulate products for markets including Australia and the United States.
Average Trading Volume: 569,690
Technical Sentiment Signal: Sell
Current Market Cap: A$259.2M
See more insights into MYX stock on TipRanks’ Stock Analysis page.